A randomized controlled clinical trial involving 100 RA patients has shown that adding RSV as an adjuvant to the conventional antirheumatic drugs (leflunomide, hydroxychloroquine, sulfasalazine, methotrexate) significantly improves the values of clinical (28 joint counts) and biochemical markers (C-reactive protein, TNF-α, erythrocyte sedimentation rate, IL-6), as well as the disease activity score [39]. This evidence concerns the gene CRP and rheumatoid arthritis.